CSBio CSBio

X
[{"orgOrder":0,"company":"Alliance Pharmaceutical Company","sponsor":"Valeo Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Valeo Pharma Licenses Canadian Rights to Ametop\u2122 Gel from Alliance Pharma","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"EGYPT","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Alliance Pharmaceutical Company"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Valeo Pharm has entered into a licensing agreement with Alliance Pharma plc for the exclusive commercialization rights to AmetopTM Gel (Tetracaine hydrochloride gel) in Canada.

            Lead Product(s): Tetracaine Hydrochloride

            Therapeutic Area: Neurology Product Name: Ametop

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Valeo Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement April 28, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY